Site is Being Upgraded

Lifespan- and healthspan-extension therapy: Shikonin, isolated from zicao/purple groomwell, may increase life span via up-regulation of its target gene BubR1 and others, 19/June/2018, 10.42 pm

Natural product-derived therapy for cardiac hypertrophy and fibrosis: A pharmaceutical mixture encompassing Sulforaphane, Myricitrin and Aspalathin (SMA) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 19/June/2017, 10.36 pm
June 19, 2018
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Sitagliptin (trade name: Januvia), a DPP4 inhibitor, increases the expression of tumor suppressors genes, such as  TIMP3, CCM3/KRIT1, TA-p73, TAp63, p53, and others, induces regression of p53-mutated human tumors, via down regulation of its target gene, 19/June/2017, 10.45 pm
June 19, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Lifespan- and healthspan-extension therapy: Shikonin, isolated from zicao/purple groomwell, may increase life span via up-regulation of its target gene BubR1 and others


From research findings to Therapeutic Opportunity: 

This study suggests, for the first time, that Shikoninby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (fig. 1).

[easy_payment currency=”USD”]

Figure 1. Natural product derived compound Shikonin may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. Shikonin as a longevity-promoting agent.   It  functions as a longevity-promoter by increasing the expression of BuBR1 and other longevity-promoting genes (fig 1).

 

 

 

 

 

 

 

 

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, a pharmaceutical mixture encompossing Shikonin or its analogues, either alone or in combination with other drugs, may be used to extend the lifespan of an individual (fig.2). This study may also through light into how some of the marine organisms enjoy exceptional longevity in salty sea-water environment.


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How Shikonin increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan- and healthspan-extension therapy: Shikonin, isolated from zicao/purple groomwell, may increase life span via up-regulation of its target gene BubR1 and others, 19/June/2018, 10.42 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.